| Filed On | Filing |
|---|---|
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Notice of Delisting or Failure to Satisfy a Listing Rule
Purchase, NY – November 5, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results... |
| 22 Oct 2026 |
8-K: Other Events
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies |
| 07 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Purchase, NY – August 6, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results f... |
| 24 Jun 2026 |
8-K: Other Events
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes |
| 22 Jun 2026 |
Form 4: Khattar Jack A., Director
Received 25,000 shares as a grant or award |
| 22 Jun 2026 |
Form 4: Monia Brett P, Director
Received 25,000 shares as a grant or award |
| 22 Jun 2026 |
Form 4: Wallace Peggy, Director
Received 25,000 shares as a grant or award |
| 22 Jun 2026 |
Form 4: Richstone Ellen B, Director
Received 25,000 shares as a grant or award |
| 22 Jun 2026 |
Form 4: Fletcher Aaron G.l., Director and 9 others
Received 25,000 shares as a grant or award |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Cognition Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was conducted virtually, and the following is a brief description of the final voting resul... |
| 04 Jun 2026 |
8-K: Regulation FD Disclosure
https://cogrx.com COGNITION THERAPEUTICS · NASDAQ: CGTX An Investigational Oral Therapy Advancing Toward Registrational Development June 2026 · Jefferies Global Healthcare Conference Zervimesine in DLB Psychosis |
| 21 May 2026 |
8-K: Other Events
- Positive Discussion on Path Forward for Registrational Program - |
| 08 May 2026 | 10-Q |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis |
| 04 May 2026 |
Form 4: Doyle John Brendan, Chief Financial Officer
Gave up 8,567 shares to cover exercise price or tax ($11K) |
| 27 Apr 2026 | ARS |
| 27 Apr 2026 | DEFA14A |
| 27 Apr 2026 | Proxy statement: annual meeting on June 17, 2026 |
Loading...